Research revealed the increased level of IL-6 and IL-21, associated with the tendency to release more IL-17A, only in NMO patients, particularly in AQP4-IgG-seropositive ones, not in patients with MS [105]. This evidence concerns the gene AQP4 and myeloid sarcoma.